[2017 Bio-health Investment Festival] Quratis "No. 1 in tuberculosis mortality: Cleaning the Blame"


Quratis, a company that develops tuberculosis medicine for adults, participated in the 2017 Bio Health Investment Festival hosted by Korea Economic Television (KERI) today (June 22) and expressed its ambition to clean up the reputation of the No. 1 TB country by creating a vaccine for adults.

"Korea needs a new vaccine because it is the most serious problem among OECD countries with the highest prevalence of tuberculosis," said Cho Kwan-gu, CEO of Quratis. "Quratis has developed adult vaccines and has successfully completed clinical doses."


In fact, the incidence of tuberculosis per 100,000 people in Korea is 86, well above the OECD average of 12. The death rate from tuberculosis is also 3.8, more than five times the OECD average.

In response, Quratis is developing a vaccine against adult tuberculosis by IDRI, a non-profit drug development organization, which is characterized by the convergence of selected protein antigens through bioinformatics analysis of tuberculosis bacteria to maintain stability and purity, which is the strength of subunit vaccine, and to enhance its efficacy.

Quratis applied for a clinical two-phase test plan late last month with the Ministry of Food and Drug Safety and plans to launch the product in 2023 after receiving three clinical awards in 2020.